Eli Lilly Licenses Amylin Diabetes Treatment in US$325 M Deal

By Business Review Editor

Pharma Deals Review: Vol 2002 Issue 29 (Table of Contents)

Published: 2 Oct-2002

DOI: 10.3833/pdr.v2002.i29.991     ISSN: 1756-7874

Section: Licensing



Eli Lilly signed a global licensing and co-development agreement with Amylin Pharmaceuticals for AC2993 for the treatment of type 2 diabetes...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details